GHTD-amide : A naturally occurring beta cell-derived peptide with hypoglycemic activity by Paule, Sarah et al.
Author's personal copy
GHTD-amide: A naturally occurring beta cell-derived peptide
with hypoglycemic activity
S.G. Paule a,1, B. Nikolovski a,1, R.E. Gray a, J.P. Ludeman a, A. Freemantle a,
R.A. Spark a, J.B. Kerr b, F.M. Ng a, P.Z. Zimmet a,c, M.A. Myers a,2,*
aDepartment of Biochemistry and Molecular Biology, Monash University, Wellington Road, Clayton, Victoria 3800, Australia
bDepartment of Anatomy and Cell Biology, Monash University, Clayton, Victoria 3800, Australia
cBaker IDI Heart and Diabetes Institute, Caulﬁeld, Victoria 3162, Australia
1. Introduction
Regulation of blood glucose primarily revolves around control
of insulin secretion and action. In addition to insulin, beta cells
produce a variety of bioactive peptides including amylin,
pancreastatin, preptin, and kisspeptins. Amylin contributes to
metabolic regulation through its actions on insulin secretion and
insulin sensitivity [6,13], and feedback signals to the brain that
reduce food intake [25]. Pancreastatin, the product of a proteolytic
cleavage of chromogranin-A unique to beta cells [26,29], and
kisspeptins [21], both reduce glucose stimulated insulin release
[11,21], whereas preptin, a cleavage product of proinsulin-like
growth factor II, appears to amplify glucose stimulated insulin
secretion [4]. Pancreatic peptides that originate from other cells
types but also inﬂuence insulin secretion include Ghrelin, which is
predominantly expressed in the gut mucosa but also found in islet
alpha cells [8] and galanin, which is expressed in nerve endings
surrounding the islets [28]. Both of these peptides inhibit insulin
secretion [10,28,1,27]. Comprehensive knowledge of all factors
controlling insulin secretion and action is required to complete our
understanding of glucose homeostasis and its disturbance in
disease states.
In the early 1970s a peptide containing preparation with insulin
potentiating activitywas isolated fromhuman urine [19,32] but the
active constituent remained chemically unidentiﬁed. Based on
chromatographic properties and activity the urinary peptide was
originally thought to be a fragment of growth hormone called
acceleratory fragment of growth hormone or AcG that derived from
pituitary extracts [19,20]. Improvements in liquid chromatography
and mass spectrometry have now allowed the puriﬁcation to near
homogeneity of this peptide from the original semi-pure prepara-
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tion. Here we show that the urinary peptide is unrelated to growth
hormone and has the sequence Gly-His-Thr-Asp-amide (GHTD-
amide) that synthetic GHTD-amide promotes storage of glucose as
glycogen andwe provide evidence that endogenous GHTD-amide is
produced by pancreatic beta cells.
2. Methods
2.1. Peptide puriﬁcation and identiﬁcation
Partial puriﬁcation of peptide from urine was performed as
described previously [20]. The lyophilized material was dissolved
in 0.1% triﬂuoroacetic acid (TFA) and puriﬁed to near homogeneity
by reverse phase HPLC chromatography on C18 and C3 columns.
First, partially puriﬁed urinary peptide was eluted isocratically for
5 min followed by a linear gradient of 50% acetonitrile on a Vydec
C18 column. Bioactive fractions were identiﬁed by measuring the
incorporation of 14C-glucose into glycogen in rat hemidiaphragm.
Active fractions were pooled and further puriﬁed using a Vydac C3
column by isocratic elution in 5% acetonitrile, 1% TFA. This stepwas
repeated a further 2 times, with bioactive fractions pooled,
lyophilized and redissolved in 0.1% TFA after each step and then
reapplied to the column. N-terminal sequence analysis was
performed on an ASI 477 ‘‘pulse liquid’’ protein sequencer with
an on-line ABI 120 A analyzer (Applied Biosystems, Inc. Model 475
A). The ES-MS and MS/MS measurements were performed on a
micromass platform instrument.
2.2. Animal experiments
GHTD-amide was synthesized by standard solid phase Fmoc
chemistry (Mimotopes, Melbourne, Australia). Male Wistar rats
were from the Monash Animal Services facility and all procedures
conformed to the NIH principles of laboratory animal care and
were approved by the Monash University Animal Ethics Commit-
tee. Rats were given free access to food and water prior to
overnight fasting. Male Wistar rats 6–8 weeks of age were fasted
then injected intravenously in the tail vein with 60 mg/kg
streptozotocin (stz). Rats with fasting blood glucose (FBG)
concentrations greater than 11 mM 5 days after stz injection
were included in the next stage of the experiment. Insulin
deﬁciency was conﬁrmed by RIA measurement of rat serum
insulin (Linco, Millipore Biosciences, Australia).
Insulin-deﬁcient rats were treated with GHTD-amide and/or
insulin in a cross-over study. Rats (n = 7) were randomized into 2
treatment groups and received by intraperitoneal injection either
1 Unit/kg insulin (bovine insulin, Sigma) followed 2 days later by
1 U/kg insulin plus 4.27 mg/kg GHTD-amide or vice versa. The
order of treatment had no effect on the experimental outcomes and
the FBGs prior to each treatment were similar (16.5  1.7 mM
versus 17.3  1.4 mM, mean  SEM, n = 7). After injection, blood
glucose was measured at regular time intervals over 2 h.
2.3. Glycogen synthesis
Glycogen synthesis was measured in HepG2 human hepatoma
cells and C2C12 rat myotubes. Cells were maintained at 378C, 5%
CO2 in Dulbecco’s modiﬁed Eagle medium (Gibco BRL) and 10%
fetal bovine serum. C2C12 myoblasts were differentiated post
conﬂuence to myotubes by culturing in 5% horse serum for 3–4
days. Cells were serum starved overnight in media containing
5.5 mM glucose. The media was aspirated and replaced with fresh
media supplemented with 0.4 mCi/ml D-[U-14C] glucose and
containing insulin or GHTD-amide at the required concentrations.
After incubation at 37 8C for 2 h the mediumwas removed and the
cells were washed with ice-cold phosphate-buffered saline and
harvested. Glycogen was extracted according to the method of
Huang et al. [14]. The radioactivity incorporated into glycogen was
thenmeasured by scintillation counting. Activity was corrected for
protein content and the results expressed as the percentage of
activity compared to the basal rate of incorporation.
2.4. Peptide detection in MIN6 cell culture
MIN6 cells were cultured at 37 8C, 5% CO2 in DMEM with 10%
FCS. For analysis of peptide secretion, a near conﬂuent layer of cells
was washed then incubated in serum free media for 24 h.
GHTD-amide in cell culture media was detected by reverse
phase-HPLC chromatography with a Photo Diode Array (PDA)
equipped Shimadzu 10A-VP system. Samples were centrifuged at
13,000  g for 5 min before loading onto Phenomenex Luna(2),
10.0 or 4.6 mm i.d.  250 mm C18 columns that had been
equilibrated with 10% buffer B (90% acetonitrile, 0.1%, v/v,
H3PO4, 2.5 mM octane sulfonic acid), at 2.5 (10.0 mm i.d.) or 1.0
(4.6 mm i.d.) ml/min. After sample injection buffer Bwas increased
over a linear gradient of buffer A (milliQ water with 0.1%, v/v,
H3PO4 and 2.5 mM octane sulfonic acid) to 100% over 25 min. The
retention times of synthetic GHTD-amide were 16.89 (10.0 mm
i.d.) or 16.29 (4.6 mm i.d.) minutes and a standard curve using
known amounts of GHTD-amidewas established for quantiﬁcation
of unknown amounts of peptide. PDA spectra and Matrix Assisted
Laser Desorption Time Of Flight Mass Spectrometry (MALDI-TOF)
were used to verify the molecular weight and peptide composition
of the putative GHTD-amide in samples. MALDI-TOF and MALDI-
peptide mass ﬁngerprint (PMF) spectra were acquired using an
Applied Biosystems 4700 MALDI-TOF/TOF mass spectrometer;
data were analyzed using GPS explorer software.
2.5. Antibodies, radioimmunoassay and immunoﬂuorescence
GHTD-amide conjugated to diphtheria toxoid via an amino
terminal cysteine residue was used to immunize rabbits and mice
(Institute of Medical and Veterinary Science, Adelaide, Australia).
Serum was collected after primary inoculation and 3 booster
injections.
An analogue of GHTD-amide containing a tyrosine (Y) at the
amino terminus (YGHTD-amide) was labeled with Sodium
125Iodide (Amersham) by chloramine-T oxidation. Labeled peptide
was separated from unbound label using Sep-Pak C18 cartridges.
Between 30 and 50,000 cpm of 125I-YGHTD-amide per tube was
mixed with rabbit anti-sera raised to GHTD-amide, the sample
containing competing peptide and a buffer containing ﬁsh skin
gelatin. After equilibration overnight at 4 8C the immune com-
plexes were precipitated with a precipitating system for immune
complexes (Linco, Millipore Biosciences, Australia) and centrifuga-
tion and the amount of 125I in the precipitate was measured.
Peptide analogues for competition were synthesized by standard
methods (GL Biochem, Shanghai, China).
Indirect immunoﬂuorescence was performed on formalin ﬁxed,
parafﬁn embedded tissue sections. Mouse tissue sections were cut
to a thickness of 5mm and mounted on a positively charged glass
slides. A panel of human endocrine tissues was purchased from
Abcam Ltd., Cambridge, UK. Tissues included were adrenal,
maxillary gland, thyroid (fetal), brain (pituitary gland), parathyroid
and pancreas. Antibodieswere guinea pig anti-insulin (Dako), anti-
GHTD-amide, rabbit anti-guinea pig FITC conjugate (Dako) and
Alexaﬂuor 568 conjugated anti-rabbit (Molecular Probes).
For immunogold electron microscopy rat pancreas was ﬁxed in
cacodylate-buffered 4% paraformaldehyde/0.5% glutaraldehyde and
embedded in LR-white. Ultra-thin sections onnickel formvar coated
grids were blocked with 0.1% ﬁsh skin gelatin for 1 h. Primary
antibodies were 1:200 dilutions of preimmune or immune anti-
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GHTD-amide rabbit sera and secondary antibody was 1:80 dilution
of goat anti-rabbit conjugated to 10 nm gold (Aurion, Costerwegs,
The Netherlands). Sections were stained with lead citrate before
visualization by transmission electron microscopy. Gold particles
decorating the dense core and halo of secretory granules were
counted on 5 randomly selected beta cells from preimmune and
immune serum incubations of each of 2 rat pancreases.
2.6. Statistics
Statistical analysis of data used GraphPad Prism software.
Student’s t-testwas used for between group comparisons and group
sizes and p values are as described in the ﬁgure legends. Animal data
were baseline corrected and analyzed by Student’s t-test.
3. Results
3.1. Puriﬁcation and sequencing of the urinary peptide
The active constituent was puriﬁed from semi-puriﬁed urine
extracts using a four-step reverse-phase HPLC procedure employ-
ing Vydac C18 and C3 columns with bioactivity conﬁrmed at each
step by assay of stimulation of glycogen synthesis in rat
hemidiaphragm. ES mass spectrometry identiﬁed a single charged
molecular ion species (M+H+) with a m/z ratio of 429 Da. Amino
acid sequencing and ES-MS/MS fragmentation identiﬁed an alpha-
amidated tetrapeptide Gly-His-Thr-Asp.
3.2. Effects of GHTD-amide on glycogen synthesis
The tetrapeptide GHTD-amide was synthesized and tested for
stimulation of glycogen synthesis in HepG2 cells and C2C12
myotubes. In HepG2 cells the peptide signiﬁcantly increased D-
[U-14C]-glucose incorporation into glycogen at concentrations
ranging from 1 pM to 1 nM to levels similar to that induced by
10 nM insulin (Fig. 1A). At a concentration of 100 pM GHTD-amide
was more potent than 1 nM insulin (p < 0.05). Evidence of high
dose inhibition was apparent with 10 nM GHTD-amide showing
signiﬁcantly reduced activity compared to the optimally active
concentration of 100 pM GHTD-amide (p = 0.05).
In C2C12myotubes GHTD-amide stimulated glycogen synthesis
but to a lesser degree andwith lower potency than inHepG2 cells. D-
[U-14C]-glucose incorporation into glycogen was signiﬁcantly
greater than basal at concentrations of 1 and 10 nM (p< 0.05)
but not at 0.1 and 100 nM (p > 0.2) (Fig. 1B). Insulin (10 nM)
increased glycogen synthesis by 80% and 117% in C2C12 and HepG2
cells respectivelywhereasGHTD-amide caused increases of 40% and
260% in the respective cell models, further reinforcing the greater
potencyof thepeptide inHepG2cells. Therewasnoadditive effect of
GHTD-amide and insulin in C2C12 cells with the combined
treatments not signiﬁcantly different to GHTD-amide alone
(Fig. 1B). Addition of GHTD-amide to 10 nM insulin caused an
apparent decrease in glycogen synthesis compared to 10 nM insulin
alone but this did not reach statistical signiﬁcance (p = 0.4–0.5).
3.3. Hypoglycemic activity of GHTD-amide in insulin-deﬁcient rats
Hypoglycemic activity in combination with insulin was tested
in insulin-deﬁcient Wistar rats (Fig. 2). This model was chosen to
minimize complications due to endogenous insulin secretion.
Injection of the rats with streptozotocin successfully ablated
insulin production by the pancreatic beta cells as shown by a
substantial decrease in serum insulin from (mean  SEM)
2.2  0.6 ng/ml prior to stz treatment to 0.28  0.08 after treatment.
Fasting blood glucose prior to insulin tolerance tests were 16.5  1.7
and 17.3  1.4 mM for insulin and insulin plus GHTD-amide
respectively. Injection of the rats with 1 U/kg insulin caused a
signiﬁcant reduction in blood glucose with the largest average
decrease of 8.3 mM occurring after 90 min (Fig. 2). When GHTD-
amide was combined with the insulin injection blood glucose
decreased by 11.1 mM after 90 min and was lower than for the
insulin treatment throughout the time-course.
3.4. Immunochemical localization of GHTD-amide peptide
A rabbit anti-serum was raised to the amidated carboxyl-
terminus of synthetic GHTD-amide conjugated to diphtheria
Fig. 1. Synthetic GHTD-amide promotes glycogen synthesis and enhances insulin-
mediated glucose lowering activity. (A) Glycogen synthesis in HepG2 cells
incubated with 1 or 10 nM insulin (white bars), 1 pM to 10 nM GHTD-amide
(grey bars) or control (black bar). Both insulin and GHTD-amide signiﬁcantly
increased D-[U-14C] glucose incorporation into glycogen compared to basal
(p < 0.05 for each treatment compared to basal, Student’s t-test), n = 9 for each
treatment and standard errors are shown by bars. (B) Glycogen synthesis in C2C12
myotubes incubated with 10 nM insulin (white bars), 0.1–100 nM GHTD-amide
(grey bars), 10 nM insulinwith 0.1–100 nMGHTD-amide (light grey bars) or control
(black bar). Both insulin and GHTD-amide at 1 and 10 nM signiﬁcantly increased D-
[U-14C] glucose incorporation into glycogen compared to basal (p < 0.05 for each
treatment compared to basal, Student’s t-test), n = 9 for each treatment and
standard errors are shown by bars.
Fig. 2. Reductions in blood glucose after injection of insulin or insulin and GHTD-
amide. Insulin-deﬁcient male Wistar rats (n = 7) were injected with insulin at 1 U/
kg (solid line) or insulin with 4.27 mg/kg GHTD-amide in a cross-over study and
blood glucose measured at regular intervals for 2 h. The difference in blood glucose
between treatments was signiﬁcant at 90 and 120 min (p < 0.05, Student’s t-test).
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toxoid. The speciﬁcity of the rabbit anti-serumwas tested using an
iodinated variant of the peptide, 125iodo-YGHTD-amide, and
competition for binding to the anti-GHTD-amide serum by
tetrapeptide sequence variants of GHTD-amide (Fig. 3). All
peptides containing HTD-amide effectively competed with
125iodo-YGHTD-amide for binding to the anti-serum regardless
of the amino acid in the ﬁrst position. Substitution of His with Val,
Asp with Asn or Thr with Ala each eliminated or signiﬁcantly
reduced competition, indicating that all three residues are required
to form the epitope (Fig. 2). These results identify the epitope
recognized by anti-GHTD-amide as HTD.
A range of tissues were screened by indirect immunoﬂuores-
cence using anti-GHTD-amide including pancreas, liver, muscle,
kidney and adipose tissue from mouse and the endocrine glands,
adrenal, maxillary, thyroid (fetal), brain (pituitary gland), para-
thyroid and pancreas from human. Indirect immunoﬂuorescence
identiﬁed staining of pancreatic islets of both mouse and human
(Fig. 4B and D). All other tissues showed no staining. In bothmouse
and human the rabbit anti-serum co-localized with an antibody to
insulin (Fig. 4C, E and F), which identiﬁes the GHTD-amide positive
cells as pancreatic beta cells. There was no staining of islets
apparent with pre-immune serum (not shown). To further conﬁrm
beta cell localization, mouse monoclonal antibodies were raised to
Fig. 3. The rabbit anti-serum raised to GHTD-amide recognizes the HTD-amide
sequence. Radio-immunoprecipitation of 125I-YGHTDwas performed using a rabbit
anti-serum raised to diphtheria toxoid-conjugated GSGSGHTD-amide. Competition
with various peptides was performed at the concentrations shown (in microgram
per ml). All competing peptides are alpha-amidated. The His, Thr and amidated Asp
all contribute to the epitope.
Fig. 4. Antibodies to GHTD-amide decorate pancreatic islets ofmouse and human and co-localize with insulin. Amousemonoclonal antibody and rabbit anti-sera were raised
to GHTD-amide conjugated to diphtheria toxoid. Tissue sections were stainedwith the GHTD-amide antibody and/or an anti-insulin antibody raised in guinea pig (Dako) and
anti-rabbit or anti-mouse IgG conjugated to Alex568 (Molecular probes) and/or anti-guinea pig IgG conjugated to FITC (Dako). (A)Mouse pancreas stainedwith amonoclonal
antibody that binds to GHTD-amide. (B and C) Amouse pancreatic islet stainedwith rabbit anti-GHTD-amide (B) and anti-insulin (C). (D–F) Human pancreas showing an islet
with a central ductule (Dako) stainedwith anti-GHTD-amide (D), anti-insulin (E) and an overlay of D and E. (G–I) A singleMIN6mouse islet beta cell stained with anti-GHTD-
amide (G), anti-insulin (H) and an overlay (I) showing co-localization in cytoplasmic vesicles. Scale bars for (C) and (E) are 50 mm and for (H) 25mm.
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the GHTD-amide diphtheria toxoid conjugate. Surprisingly all the
monoclonals raised were of the IgM isotype. Supernatant from the
best producing clone was used to stain mouse pancreas by indirect
immunoﬂuorescence and once again staining was restricted to
pancreatic islets (Fig. 4A). The subcellular localization of anti-
GHTD-amide immunoreactivity in pancreatic beta cells was
explored further using the mouse islet beta cell line MIN6.
Staining of MIN6 cells with antibodies to insulin and the anti-
GHTD-amide anti-serum and confocal imaging revealed co-
localization of anti-GHTD-amide and insulin binding in the
cytoplasm of MIN6 cells (Fig. 4G–I). The overlay shows that while
the relative staining intensity with insulin (green) and anti-GHTD-
amide (red) varies themajority of vesicles in the cytoplasm stained
with both antibodies (Fig. 4I).
Immunogold staining for GHTD-amide and electronmicroscopy
was performed on rat pancreas to further deﬁne the site of GHTD-
amide immune reactivity within beta cells. For sections stained
with anti-GHTD-amide, there was a signiﬁcant increase in the
density of 10 nm gold particles decorating dense core secretory
granules compared to pre-immune controls (Fig. 5) with an
average of 61% of granules decorated compared to 33% for the
preimmune serum (Fig. 5A and B). Gold particles were distributed
throughout the cytoplasmwith clusters apparent in the dense core
of some secretory granules (Fig. 4A arrowed), whereas preimmune
serum showed a lower density and more even distribution of gold
particles (Fig. 5B). Counting of gold particles across 10 randomly
selected 12.8 mm2 images showed that 50% of gold particles were
associated with secretory granules divided into 35% associated
with the dense core and 15% with the halo (Fig. 5C).
3.5. GHTD-amide in cell culture media conditioned by MIN6 beta cells
Detection of antigenic structures reactivewith theGHTD-amide
anti-serum in secretory granules of pancreatic beta cells suggested
an islet beta cell origin for urinary GHTD-amide. This was tested
using the mouse beta cell line MIN6. Serum free media was
conditioned by conﬂuent MIN6 cells for 24 h. Media was collected
and concentrated and analyzed for GHTD-amide by HPLC andmass
spectrometry. A peptide species that absorbed at 214 nm with a
retention time on C18 reverse phase HPLC (16.2 min) equivalent to
that of synthetic GHTD-amide was identiﬁed in conditionedmedia
but was absent in unconditioned media (Fig. 6). MALDI-TOF mass
spectrometry on the 16–17 min fraction revealed a peptide species
with average molecular weight of 429 Da and ms/ms produced
fragment sizes consistent with GHTD-amide as assigned by the ion
Fig. 5. (A) Electronmicrograph showing decoration of secretory granules by 10 nm gold particles marking binding by the anti-GHTD-amide rabbit anti-serum and (B) sparser
numbers of gold particles on a section stained with the pre-immune serum. Magniﬁcation 25,000. Scale bar 0.6mm. (C) The number of 10 nm gold particles decorating the
dense core or halo of secretory granules from 10 randomly selected 12.8 mm2 images. Gold particles that could not be attributed to secretory granules were designated as
‘‘other’’.
Fig. 6. GHTD-amide is secreted by MIN6 cells. Serum free media conditioned for
24 h by a conﬂuent layer of MIN6 cells was separated by reverse phase HPLC.
Absorption at 214 nm for the conditioned media (solid line) and unconditioned
serum free media (dashed line) identiﬁed the appearance of several peaks in
conditioned media, including a species with a retention time equivalent to
synthetic GHTD-amide (16.2 min, arrowed). This species was identiﬁed as GHTD-
amide by MALDI-TOF mass spectrometry.
Author's personal copy
fragmentation tool of the GPS explorer software (Table 1). Thus
GHTD-amide is produced byMIN6 beta cells conﬁrming pancreatic
islet beta cells as an endogenous source of the peptide.
3.6. A potential precursor of GHTD-amide is not in the annotated
human proteome
A bioinformatics search was performed in an attempt to
identify a precursor protein for GHTD-amide. The precursors of all
known amidated peptides and proteins contain a Gly adjacent to
the C-terminal amidated amino acid [12] and this is generally
ﬂanked by a basic residue that serves as a protease cleavage site.
Alternatively, the amidated sequence may occur at the C-terminus
of the precursor protein with a Gly as the last amino acid. Hence,
the sequence GHTDG was used to BLAST search the NCBI non-
redundant human protein sequence databases and Swissprot,
which contain all characterized and predicted proteins from the
human genome. Five proteins were identiﬁed that contain the
sequence GHTDG. The ﬁrst 4 of these proteins are members of an
evolutionary conserved family of transducin-like enhancer of split
transcriptional repressors (TLE1 through to TLE4) that contain WD
domains characterized by a GH dipeptide followed 11–24 amino
acids later by WD [5]. The GHTDG sequence occurs in a conserved
WD domain in this TLE protein family. The other protein is
transforming acidic coiled coil containing protein 2 (TACC2) [16].
These proteins are all widely expressed, restricted to the cell
nucleus and lack potential protease cleavage sites adjacent to the
C-terminal of the GHTDG sequence. There is a higher than expected
chance of the GHTDG sequence occurring in these proteins due to
the presence of several GH dipeptidemotifs in TLE proteins and the
high content of Gly (8.8%) and acidic residues, including Asp (5.5%),
in TACC2. No other GHTDG containing proteins were found in the
annotated human proteome.
4. Discussion
More than 30 years ago a peptide with insulin potentiating
activity was isolated from human urine [19,20] but the technology
to identify the peptidewas not then available. Herewe have shown
that the active constituent is a tetrapeptide with the sequence
GHTD-amide. Synthetic GHTD-amide stimulated glycogen synth-
esis in a hepatoma cell line and C2C12 myotubes and enhanced
insulin-mediated glucose lowering in an insulin-deﬁcient rat
model of diabetes conﬁrming that GHTD-amide is the active
molecule originally described in human urine.
The original puriﬁcation of the urinary peptide found the
peptide to only be active in the presence of insulin [19,20,32]. In
this study activation of glycogen synthesis in liver andmuscle cell
lines in the absence of insulin identiﬁes an insulin-like activity
attributable to GHTD-amide. This activity showed a high-dose
inhibition effect, with reduced activity at concentrations above
100 pM in HepG2 cells. Reduced cellular responses at high
concentrations are also frequently observed for insulin due to
negative co-operativity in binding to the insulin receptor [9]. This
may suggest that GHTD-amide is also operating through a
receptor but as yet this has not been identiﬁed. Hypoglycemic
activity in an insulin-deﬁcient animal model may therefore be
attributable to direct actions of the peptide or to the insulin
potentiating activity originally described for the peptide pre-
parations from urine.
Alpha-amidation of the carboxyl terminal amino acid is
common in secreted peptide hormones, growth factors and
neuropeptides [12]. However, alpha amidated aspartic acid
appears to be uncommon with the only example being an opioid
peptide from frog skin called deltorphin or dermenkephalin [2,23].
To our knowledge GHTD-amide is the ﬁrst mammalian derived
peptide described that contains alpha-amidated aspartic acid.
The rabbit anti-serum raised to a diphtheria toxoid/GHTD-
amide conjugate bound to pancreatic islets and no other tissues.
The speciﬁcity of the anti-serum for the C-terminus of the
peptide, the unique nature of amidated Asp at the C-terminus,
and the demonstration that MIN6 cells release GHTD-amide into
cell culture media suggest that pancreatic beta cells are an
endogenous source of this peptide. At this stage it is unclear
whether GHTD-amide is co-secreted with insulin in response to
glucose and amino acid stimuli since the detection methods
currently available lack sufﬁcient sensitivity to perform these
experiments and the quantities released from MIN6 cells are
small. A search for circulating endogenous GHTD-amide using
the radioimmunoassay described here and a LC/MS/MS bioana-
lytical method both failed to detect the peptide in human or
rodent plasma (data not shown) indicating that, if the peptide is
present in the circulation, concentrations are below the lower
limit of detection (0.5 ng/ml) of these methods. Co-localization
with insulin in secretory granules of MIN6 cells and immunogold
staining of dense core secretory granules suggest that further
investigation of how GHTD-amide is released from MIN6 beta
cells is warranted.
Peptides in urine usually derive from fragmented circulating
plasma proteins and bioactive peptides [7]. It would be anticipated
that GHTD-amide, like other alpha-amidated peptides, is pro-
cessed from a larger precursor protein and released into the
circulation, but no protein fulﬁlling the criteria for a precursor is
present in the annotated human proteome. A precedent for
endogenous alpha amidated tetrapeptides for which a precursor
protein is not known is the endomorphins. Endomorphins were
ﬁrst isolated from brain and bind with high afﬁnity and selectivity
to mu opioid receptors [22,31]. A search for precursor proteins for
endomorphin-1 (Tyr-Pro-Trp-Phe-amide) and endomorphin-2
(Tyr-Pro-Phe-Phe-amide) found no evidence of such proteins in
the human proteome [30] and it has even been suggested that they
may be synthesized non-ribosomally [24]. Many peptide hormone
precursors are short polypeptides encoded by small messenger
RNA that can be underrepresented in cDNA libraries and easily
overlooked by gene prediction algorithms. There has been some
success in identifying novel peptide hormone/neuropeptide-
encoding genes using more complex algorithms and hidden
Markov models [3,18]. However, these approaches are not
guaranteed of success since the conserved bioactive regions
encoded by some neuropeptide genes are interrupted by introns,
as is seen in the neuropeptide Y family where the encoded RQRY-
amide motif contains an intron in the codon for the penultimate
residue in the RQRY peptide sequence [15,17]. Hence, it is possible
that genes encoding precursor proteins for GHTD-amide and
endomorphins exist but as yet have not been detected due to their
small size or interruption of the encoded tetrapeptide sequences
by introns. Resolution of this problem will require either
puriﬁcation of the unprocessed precursor proteins, extensive
expression screening of small and rare cDNA clones from source
tissues or a clear demonstration of non-ribosomal synthesis.
Table 1
MALDI-TOF fragmentation of GHTD-amide from media conditioned by MIN6 cells.
Mass (Da) 429 385 269.9 251.9 241.0 196.0 169.0 100.1 70.0
Assignment Parent molecule m-T1, a4 a3 d3b HT b2 a2 d2a w1a
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In conclusion, GHTD-amide is a novel islet beta cell peptide that
stimulates glycogen synthesis in muscle and liver cells and
enhances insulin-mediated blood glucose lowering in an insulin-
deﬁcient animalmodel of diabetes.While themode of biosynthesis
of the peptide remains unknown this activity and its production by
pancreatic beta cells suggest a role in normal glucose homeostasis.
Further study of the physiological role of GHTD-amide in health
and disease will provide further insights into the regulation of
blood glucose.
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